💊 Off-Label Longevity Drug Access Simulator

No Approved Indication for Longevity Use

Placeholder: aging is not a recognized indication by regulators.

• 0: Approved anti-aging drugs (placeholder figure)
• dozens: Trials underway (placeholder figure)
• few: Regulatory bodies engaged (placeholder figure)
• years: Time to approval est. (placeholder figure)

Why longevity lacks an indication

Placeholder: aging is a process, not a disease label.

Placeholder: regulators require disease-specific endpoints.

Physician Off-Label Prescribing Pathway

Placeholder: doctors may legally prescribe approved drugs off-label.

• common: Off-label prescriptions (placeholder figure)
• present: Physician oversight (placeholder figure)
• moderate: Liability exposure (placeholder figure)
• yes: Documentation required (placeholder figure)

How the pathway works

Placeholder: clinician judgment guides off-label use.

Placeholder: supervision lowers risk versus self-access.

Self-Sourced and Online Access Risks

Placeholder: unsupervised online purchasing bypasses safeguards.

• many: Online sellers unverified (placeholder figure)
• elevated: Dosing errors (placeholder figure)
• limited: Legal recourse (placeholder figure)
• low: Patient awareness (placeholder figure)

Risks of bypassing physicians

Placeholder: no clinical vetting of suitability or interactions.

Placeholder: self-sourcing removes key safety checks.

Quality and Counterfeit Concerns

Placeholder: unregulated supply chains invite counterfeits.

• notable: Counterfeit rate est. (placeholder figure)
• high: Potency variance (placeholder figure)
• present: Contamination reports (placeholder figure)
• rare: Testing access (placeholder figure)

Supply chain vulnerabilities

Placeholder: gray-market products lack batch verification.

Placeholder: counterfeit risk rises without physician sourcing.

Informed Consent and Monitoring Importance

Placeholder: monitoring and consent mitigate off-label harms.

• yes: Baseline labs recommended (placeholder figure)
• periodic: Follow-up visits (placeholder figure)
• improves: Adverse event tracking (placeholder figure)
• higher: Patient understanding (placeholder figure)

Why monitoring matters

Placeholder: regular testing catches adverse effects early.

Placeholder: consent plus monitoring is the safest combination.